Details of the Drug Reposition

General Information of This Drug (ID: DMWP1BH)

Drug Name
Tazemetostat   DMWP1BH
Synonyms
EPZ-6438; 1403254-99-8; EPZ6438; UNII-Q40W93WPE1; N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4'-(morpholinomethyl)-[1,1'-biphenyl]-3-carboxamide; Q40W93WPE1; EPZ 6438; E7438; (1,1'-Biphenyl)-3-carboxamide, N-((1,2-dihydro-4,6-dimethyl-2-oxo-3-pyridinyl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4'-(4-morpholinylmethyl)-
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)
1 Approved Indication(s)
Indication Name Indication ID ICD-11 Status REF
Follicular lymphoma DISVEUR6 2A80 Approved [1]
------------------------------------------------------------------------------------
3 Phase 2 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Malignant rhabdoid tumour DIS46HZU 2A00.1Y Phase 2 [2]
Solid tumour/cancer DISZR48F 2A00-2F9Z Phase 2 [3]
Mesothelioma DISKWK9M 2C51.2 Phase 2 [3]
------------------------------------------------------------------------------------
1 Phase 1/2 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Diffuse large B-cell lymphoma DISSACK3 2A81 Phase 1/2 [3]
------------------------------------------------------------------------------------
1 Phase 1 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Synovial sarcoma DISEZJS7 2B5A Phase 1 [3]
------------------------------------------------------------------------------------

References

1 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)